Randomized phase 2 trial of erlotinib in combination with high‐dose celecoxib or placebo in patients with advanced non‐small cell lung cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|18|3298-3306

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.18, 2015-09, pp. : 3298-3306

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase II Randomized Study of Cisplatin-Pemetrexed plus either Enzastaurin or Placebo in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 82, Iss. 1, 2012-01 ,pp. : 25-29

Karger

Access to resources Recommend Favorite

The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed Versus Placebo Immediately Following Induction First-line Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer

By  

Reviews on Recent Clinical Trials, Vol. 8, Iss. 1, 2013-01 ,pp. : 23-28

Bentham Science Publishers

Access to resources Recommend Favorite

Erlotinib in African Americans With Advanced Non–Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 2, 2014-08 ,pp. : 182-191

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dose Escalation Study of Paclitaxel in Combination with Fixed-Dose Irinotecan in Patients with Advanced Non-Small Cell Lung Cancer (JCOG 9807)

By  

Oncology, Vol. 66, Iss. 2, 2004-05 ,pp. : 94-100

Karger

Access to resources Recommend Favorite

Population pharmacokinetics of erlotinib in Japanese patients with advanced non‐small cell lung cancer

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 40, Iss. 2, 2015-04 ,pp. : 232-239

John Wiley & Sons Inc

Access to resources Recommend Favorite